MRC37 |
Catalog No.GC79630
One-Click Copy Product Info
|
MRC37 is a high-affinity TRIM21 ligand with a K d of 0.4 µM.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vitro, MRC37 (0.4 μM; 48 h) binds to purified TRIM21 PRYSPRY domain with high affinity (0.4 μM) and exhibits no TRIM21-dependent cytotoxicity in wild-type RPE-1 cells at concentrations up to 20 μM for 48 h[1]. MRC37 (1 μM) monovalent ligand does not drive ternary complex formation between TRIM21 and H2B-mEGFP-Halo in RPE-1 cells, nor does it affect TRIM21 PRYSPRY binding when modified to generate TRIMTAC derivatives[1]. MRC37 (0.01-100 μM; 48 h) does not induce degradation of monomeric mEGFP-Halo, oligomeric CAV1-mEGFP-Halo, or oligomeric Cavin1-mEGFP-Halo in RPE-1 cells at concentrations up to 100 μM for 48 h[1]. MRC37 (50-100 μM; 15 h) inhibits TRIM21-mediated antiviral activity in HEK293T cells and TRIM21-dependent protein degradation in RPE-1 cells in a dose-dependent manner[1]. MRC37 (5 μM) does not degrade oligomeric Myd88 Myddosomes in stimulated cells, but can compete with TRIMTAC MRC414 to partially reverse inhibition of seeded tau aggregation in HEK293 reporter cells[1].
References:
[1]. Luptak J, et al. State-selective small molecule degraders that preferentially remove aggregates and oligomers. Nature communications. 2025 Nov 25;16(1):10486.
| Cas No. | SDF | ||
| Formula | C30H41N5O4 | M.Wt | 535.68 |
| Solubility | DMSO: ≥ 250 mg/mL (466.70 mM) | Storage | Sealed storage, away from moisture |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8668 mL | 9.3339 mL | 18.6679 mL |
| 5 mM | 373.4 μL | 1.8668 mL | 3.7336 mL |
| 10 mM | 186.7 μL | 933.4 μL | 1.8668 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)